Stanford Cancer Center, 875 Blake Wilbur Drive, CC 2232, Stanford, CA 94305, United States.
Crit Rev Oncol Hematol. 2016 Oct;106:99-107. doi: 10.1016/j.critrevonc.2016.07.001. Epub 2016 Jul 5.
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of rare non-Hodgkin lymphomas that arise in the skin. In advanced stages, CTCL becomes systemic and is associated with poor prognosis. Diagnosis of CTCL and treatment of early-stage disease with topical therapies often occurs under the care of a dermatologist. Community oncologists see few patients with CTCL due to direct referrals from dermatologists to academic or lymphoma specialty centers. However, some patients will continue to be managed in a community setting. Currently there is no evidence-based stepwise algorithm for treatment of patients with CTCL, and guidelines suggest a wide range of systemic therapies, including biologics, targeted agents, and more traditional chemotherapies. To provide optimal care in a community setting, oncologists must become familiar with newer nonchemotherapeutic treatment options. This review highlights romidepsin, a histone deacetylase inhibitor approved for the treatment of patients with CTCL who have received ≥1 prior systemic therapy.
皮肤 T 细胞淋巴瘤（CTCL）是一组罕见的非霍奇金淋巴瘤，起源于皮肤。在晚期，CTCL 会发展为系统性疾病，并伴有预后不良。CTCL 的诊断和早期疾病的局部治疗通常由皮肤科医生负责。由于皮肤科医生直接将患者转诊至学术或淋巴瘤专业中心，社区肿瘤医生很少看到 CTCL 患者。然而，一些患者仍将在社区环境中接受治疗。目前，尚无针对 CTCL 患者的循证分级治疗算法，指南建议采用多种全身治疗方法，包括生物制剂、靶向药物和更传统的化疗药物。为了在社区环境中提供最佳治疗，肿瘤医生必须熟悉新型非化疗治疗方案。本文重点介绍罗米地辛，这是一种组蛋白去乙酰化酶抑制剂，适用于已接受≥1 种既往全身治疗的 CTCL 患者。
